PT  - JOURNAL ARTICLE
AU  - Grewal, Ekjot
AU  - Sutarjono, Bayu
AU  - Mohammed, Ibbad
TI  - Angioedema, ACE inhibitor and COVID-19
AID  - 10.1136/bcr-2020-237888
DP  - 2020 Sep 01
TA  - BMJ Case Reports
PG  - e237888
VI  - 13
IP  - 9
4099  - http://casereports.bmj.com/content/13/9/e237888.short
4100  - http://casereports.bmj.com/content/13/9/e237888.full
SO  - BMJ Case Reports2020 Sep 01; 13
AB  - SARS-CoV-2, the virus responsible for COVID-19, binds to the ACE2 receptors. ACE2 is thought to counterbalance ACE in the renin-angiotensin system. While presently it is advised that patients should continue to use ACE inhibitors or angiotensin receptor blockers, questions still remain as to whether adverse effects are potentiated by the virus. Here, we report a case of a 57-year-old man, unknowingly with COVID-19, who presented to the emergency department with tongue swelling, shortness of breath and difficulty in speaking following 4 months taking benazepril, an ACE inhibitor. Finally, we also describe possible pathways that exist for SARS-CoV-2 to interact with the mechanism behind angioedema.